Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices.
It is a $107B healthcare company. Revenue grew 8.5% over the last year, it keeps 14¢ of every dollar of sales as profit, and its net debt equals ~2.5 years of free cash flow. It trades at 28.5× earnings — near the lowest of its own history.
- Website
- stryker.com
- Location
- Portage, MI
- Employees
- 56 000
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong growth and quality.
Valuation69
- P/E vs own history1th pct · 25/25
- FCF yield4.4% · 12/25
- P/S4.1x · 20/25
- EV/EBITDA18.9x · 12/25
Growth85
- Revenue CAGR10.1% · 20/25
- Net income CAGR13.0% · 20/25
- EPS CAGR ~5Y14.8% · 20/25
- Fwd implied growth68.3% · 25/25
Profitability72
- ROIC9.5% · 12/25
- ROE16.4% · 20/25
- Net margin14.4% · 20/25
- Operating margin21.3% · 20/25
Health62
- Altman Zn/a · 0/25
- Current ratio2.16 · 25/25
- Interest coverage10.3x · 25/25
- Net cash / debtD/A 25% · 12/25
Quality90
- Piotroski F6/9 · 15/25
- Beneish M-2.63 · 25/25
- FCF conversion126% · 25/25
- Margin stabilityσ 2.5% · 25/25
Moat68
- ROIC >12% years2/10 yrs · 0/25
- Median gross margin64.0% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 8.2% · 18/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2023MilestoneThe first two Directed Energy Maneuver-SHORAD Strykers were delivered in early 2023 for training with soldiers
- 2021MilestoneThe first four Stryker M-SHORAD vehicles were deployed to Germany in April 2021 as part of the 5th Battalion, 4th…
- 2020MilestoneBecause the unarmored Humvee-based Avenger lacks survivability and range to keep up with maneuver forces and hold…
- FY2018FinancialBest year on record$3.55B net income
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $10B$11.3B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2002MilestoneThe Army formally renamed the IAV as the "Stryker" after two unrelated U.S
- 2000ProductThe service launched the Interim Armored Vehicle competition
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (65.3%)
- Strong cash conversion — FCF is 18.2% of revenue
- Interest covered 10.3× by operating earnings
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+8.5% YoY
- Profitable — makes more than it spends$3.73B TTM
- Profit growing — earnings are higher than last year+10.8% YoY
- Generates cash — cash left after running and investing$4.70B TTM
- Debt under control — could handle its obligations~2.5y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$107B market cap
- Not printing shares — share count not ballooning — you keep your slice+1.6% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 50/100
- Pays a dividend — returns cash to shareholdersyield 1.24%
- Valuation not extreme — price not wildly above earningsP/E 28.5
Peer comparisonStryker Corporation vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| SYK this company | $106.5B | 28.5 | +8.5% | 14.4% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: SYK vs LLY · SYK vs JNJ · SYK vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/SYK
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of SYK on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $277.70 · market cap $107B.